The feed-forward loop of type I interferons (IFNs) production and subsequent immunopathology of systemic lupus erythematosus (SLE) has been hypothesised to be disrupted with inhibition of IFNα or type I IFN receptor subunit 1 (IFNAR). This systematic review and meta-analysis present the treatment efficacy and safety profile of monoclonal antibodies inhibiting IFNα or IFNAR.
Methods
A search was done using Medline, Embase and ClinicalTrials.gov for biologics targeting IFNα or IFNAR in SLE up to 3 Jan 2020. For the meta-analysis, analyses of binary variables were pooled using odds ratio (OR) with the Mantel Haenszel model.
Results
Anifrolumab 300 mg (n = 3 studies, 927 patients) was more effective than placebo in achieving SRI(4) (pooled OR = 1.91, CI 1.11-3.28, P = 0.02) and BICLA response (pooled OR = 2.25, CI 1.72-2.95, P < 0.00001). In SLE patients with high type I IFN gene signature, SRI(4) response was not achieved with anifrolumab in 2 studies, 450 patients. Treatment with IFNα and IFNAR inhibitors (n = 7 studies, 1590 patients) increased the risk of herpes zoster infection (pooled OR = 3.72, CI 1.88–7.39, P = 0.0002), upper respiratory tract infections, nasopharyngitis and bronchitis.
Conclusion
This meta-analysis substantiates IFNAR as a therapeutic target in SLE. Inhibition of type I IFNs predisposes to herpes zoster and other viral infections.
TaraborelliMCavazzanaIMartinazziN, et al.
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years.Lupus2017;
26: 1197–1204.
2.
MoscaMTaniCCarliLBombardieriS.Glucocorticoids in systemic lupus erythematosus.Clin Exp Rheumatol2011;
29: S126–S129.
3.
TeoRDhanasekaranPTaySHMakA.Mathematical processing is affected by daily but not cumulative glucocorticoid dose in patients with systemic lupus erythematosus. Rheumatology2020; 59: 2534–2543.
HallJCRosenA.Type I interferons: crucial participants in disease amplification in autoimmunity.Nat Rev Rheumatol2010;
6: 40–49.
6.
HooksJJMoutsopoulosHMGeisSAStahlNIDeckerJLNotkinsALImmune interferon in the circulation of patients with autoimmune disease.N Engl J Med1979;
301: 5–8.
7.
BanchereauJPascualV.Type I interferon in systemic lupus erythematosus and other autoimmune diseases.Immunity2006;
25: 383–392.
8.
BlancoPPaluckaAKGillMPascualVBanchereauJ.Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus.Science2001;
294: 1540.
9.
ShaoW-HCohenPL.Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther2011;
13: 202.
10.
LövgrenTElorantaM-LBåveUAlmGVRönnblomL.Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG.Arthritis Rheumat2004;
50: 1861–1872.
11.
PetriMWallaceDJSpindlerA, et al.
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.Arthritis Rheum2013;
65: 1011–1021.
12.
NikpourMDempseyAAUrowitzMBGladmanDDBarnesDA.Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus.Ann Rheum Dis2008;
67: 1069.
13.
PetriMSinghSTesfasyoneH, et al.
Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.Lupus2009;
18: 980–989.
14.
PetriMFuWRangerA, et al.
Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus.BMC Med Genom2019;
12: 4.
15.
FurieRKhamashtaMMerrillJT, et al.
Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol2017;
69: 376–386.
16.
SterneJACSavovićJPageMJ, et al.
RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J2019;
366: l4898.
17.
McGuinness LA and Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Syn Meth 2020; 1–7.
18.
SalmonJENiewoldTB.A successful trial for lupus – how good is good enough?N Engl J Med2020;
382: 287–288.
WallaceDJKalunianKPetriMA, et al.
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.Ann Rheum Dis2014;
73: 183.
21.
AlbrechtJTaylorLBerlinJA, et al.
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.J Invest Dermatol2005;
125: 889–894.
22.
FletcherJ.What is heterogeneity and is it important?Br Med J2007;
334: 94–96.
23.
DerSimonianRLairdN.Meta-analysis in clinical trials. Control Clin Trials1986;
7: 177–188.
24.
FurieRAMorandEFBruceIN, et al.
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol2019;
1: e208–e19.
25.
MorandEFFurieRTanakaY, et al.
Trial of anifrolumab in active systemic lupus erythematosus.N Engl J Med2019;
382: 211–221.
26.
BruceINamiASchwetjeE, et al.
PK/PD, safety and exploratory efficacy of subcutaneous anifrolumab in SLE: a phase-II study in interferon type I high patients with active skin disease. Arthritis Rheumatol2019; 71(Suppl 10): 4545–4548.
27.
KhamashtaMMerrillJTWerthVP, et al.
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.Ann Rheum Dis2016;
75: 1909.
28.
MerrillJTWallaceDJPetriM, et al.
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.Ann Rheum Dis2011;
70: 1905.
29.
McBrideJMJiangJAbbasAR, et al.
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.Arthritis Rheum2012;
64: 3666–3676.
30.
KalunianKCMerrillJTMaciucaR, et al.
A phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).Ann Rheum Dis2016;
75: 196.
31.
LauwerysBRDucreuxJHoussiauFA.Type I interferon blockade in systemic lupus erythematosus: where do we stand?Rheumatology2013;
53: 1369–1376.
32.
RiggsJMHannaRNRajanB, et al.
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.Lupus Sci Med2018;
5: e000261.
33.
BennettLPaluckaAKArceE, et al.
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med2003;
197: 711–723.
34.
CrowMK.Type I interferon in the pathogenesis of lupus.J Immunol2014;
192: 5459–5468.
35.
BaechlerECBatliwallaFMKarypisG, et al.
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.Proc Natl Acad Sci U S A2003;
100: 2610–2615.
36.
RatliffMLGartonJGarmanL, et al.
ARID3a gene profiles are strongly associated with human interferon alpha production.J Autoimmun2019;
96: 158–167.
37.
KnightJSKaplanMJ.Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis.2012;
24: 441–450.
CrowMK.Interferon-alpha: a therapeutic target in systemic lupus erythematosus.Rheum Dis Clin North Am2010;
36: 173–186.
40.
KyttarisVC.Chapter 64 – new treatments for systemic lupus erythematosus. In: TsokosGC (ed) Systemic lupus erythematosus.
Boston:
Academic Press, 2016, pp. 551–557.
41.
YaoYHiggsBWRichmanLWhiteBJallalB.Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus. Arthritis Res Ther2010;
12: S6.
42.
MerrillJT.For lupus trials, the answer might depend on the question. Lancet Rheumatol2019;
1: e196–e7.
43.
Ruiz-ArruzaIUgarteACabezas-RodriguezIMedinaJ-AMoranM-ARuiz-IrastorzaG.Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. Rheumatology2014;
53: 1470–1476.
44.
ApostolopoulosDMorandEF.It hasn’t gone away: the problem of glucocorticoid use in lupus remains. Rheumatology2016;
56: i114–i122.
45.
OonSHuqMGodfreyTNikpourM.Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Sem Arthritis Rheum2018;
48: 221–239.
46.
GentileGFoàR.Viral infections associated with the clinical use of monoclonal antibodies.Clin Microbiol Inf2011;
17: 1769–1775.
47.
FensterlVSenGC.Interferons and viral infections.BioFactors2009;
35: 14–20.
48.
EmodiGRufliTJustMHernandezR.Human interferon therapy for herpes zoster in adults.Scand J Infect Dis1975;
7: 1–5.
49.
MokCC.Herpes zoster vaccination in systemic lupus erythematosus: the current status.Hum Vaccin Immunother2019;
15: 45–48.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
